Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

There have been a series of reports on the association of a genetic polymorphism at the cytochrome P450 CYP2D6 gene locus with cancer susceptibility. Many of these reports have remained contradictory either because of small numbers of patients studied or because of the limitations and controversy surrounding the pharmacokinetic assay used to identify affected individuals (poor metabolizers; PMs). We have recently developed a DNA-based assay that will allow the unequivocal identification of poor metabolizers and have applied this to the study of 1635 patients with different forms of cancer. Out of 361 lung cancer patients studied no statistically significant change in the proportion of PMs relative to controls was found. However, a significant increase in the proportion of poor metabolizers or heterozygotes was seen in leukaemia, bladder cancer and melanoma patients. This could be explained by a role for CYP2D6 in carcinogen detoxification or by linkage to another cancer-causing gene.

Type

Journal article

Journal

Carcinogenesis

Publication Date

06/1992

Volume

13

Pages

1035 - 1038

Keywords

Amino Acid Sequence, Cytochrome P-450 CYP2D6, Cytochrome P-450 Enzyme System, DNA Mutational Analysis, DNA, Neoplasm, Disease Susceptibility, Genetic Carrier Screening, Humans, Inactivation, Metabolic, Mixed Function Oxygenases, Molecular Sequence Data, Neoplasms, Phenotype, Polymerase Chain Reaction, Polymorphism, Genetic